-
The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions
Sunday, November 8, 2020 - 1:47pm | 4415Read More...Biotech stocks turned around with the broader market in the week ended Nov. 6, as investors warmed to the idea of a split Congress and a change of guard at the White House. The week witnessed a flurry of earnings from several smid-cap companies. Bluebird bio Inc. (NASDAQ: BLUE) shares came...
-
Bulls, Bears Squaring Off At Biogen
Monday, March 30, 2015 - 11:31am | 464Read More...Biogen Inc (NASDAQ: BIIB) has been a huge winner for many years now, rising from below $40 in 2008 to over $475 in recent weeks, with only one decline of over 20 percent during that time. With that kind of price appreciation, it should not be a surprise to anyone that the company's...
-
JP Morgan Maintains Neutral Rating On Biogen Idec After Positive Phase 3 BG-12 Results
Monday, April 11, 2011 - 9:22am | 204Read More...JP Morgan has published a research report on Biogen Idec (NASDAQ: BIIB) after the company announced positive results for its phase 3 DEFINE trial of BG-12 in RRMS. In the report, JP Morgan writes, "Against placebo, both doses of BG-12 (240mg BID and TID) meet the primary endpoint of annual relapse...
-
Biogen Announced Positive Phase 3 Results For BG-12, Deutsche Bank Maintains Hold
Monday, April 11, 2011 - 9:15am | 129Read More...Deutsche Bank has published a research report on Biogen Idec Inc. (NASDAQ: BIIB) after the company announced positive top-line results for the BG-12 phase 3 trial this morning. In the report, Deutsche Bank writes "Biogen will likely try to publish DEFINE results at an upcoming medical meeting in...
-
Icahn Moves To Sell Biogen Idec (BIIB) After Adding another Director
Monday, March 22, 2010 - 6:03pm | 144Read More...Billionaire activist investor Carl Icahn announced that he will attempt to sell Biogen Idec Inc (Nasdaq: BIIB). Icahn Partners LP and its affiliates own 16.1 million shares, or 6% of outstanding shares, of Biogen Idec. Icahn has had a series of proxy battles with Biogen Idec and the company...
-
Roche And Biogen Idec (BIIB) Suspend Rheumatoid Arthritis Drug Program
Monday, March 8, 2010 - 9:07am | 119Read More...Swiss pharmaceutical company Roche Holding AG and Biogen Idec Inc (Nasdaq: BIIB) announced on Monday that safety concerns had caused them to suspend a program to treat rheumatoid arthritis with drug candidate ocrelizumab. The independent Data and Safety Monitoring Board had found that the potential...
-
Biogen Idec Inc (Nasdaq: BIIB) Posts Strong Earnings Growth
Tuesday, February 9, 2010 - 10:42am | 122Read More...Biotech company Biogen Idec Inc (Nasdaq: BIIB) reported a rise in 4th quarter earnings and revenue. Biogen Idec Inc said that it earned $306 million, or $1.06 per share, compared with $207 million, or 70 cents per share, for the same quarter a year earlier. Revenue for the 4th quarter was up 5% to...
